Definium's LSD-based pill meets Phase 3 goals in anxiety disorder trial

August 12, 2026 7:00 AM

Definium Therapeutics (Nasdaq: DFTX) announced that its Phase 3 Voyage study of DT120 (lysergide) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found